NCT06490380View on ClinicalTrials.gov

HRD Status Reference Standard Based on WGS

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

December 30, 2022

Primary Completion Date

December 13, 2023

Study Completion Date

June 21, 2024

Conditions
Ovarian Cancer
Interventions
DRUG

PARPi

Poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi)

Trial Locations (1)

100730

Lei Li, Beijing

All Listed Sponsors
collaborator

National Institutes for Food and Drug Control, China

OTHER

collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Lei Li

OTHER